Company Analysis
Sign in

Clinuvel Pharmaceuticals Limited (CUVL)

Nasdaq: CUVL · American Depositary Receipts · filing with the SEC since 2004
Full chart Alerts Compare
Grade5.0
◀ Past 5.0● Present 5.0▶ Future 5.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2026, as filed
Revenue$64.3M+5.2%
Net income$23.2M+0.2%
Earnings per share$0.460.0%
Operating cash flow$12.9M-52.7%
Cash$13.9M-23.0%
Debtn/a
Shareholders’ equity$189M+20.3%
Shares, diluted50.7M+0.7%
Return on equity12.3%
The recordfrom its filings
Filings in 202634
Newest filingOct 30 · 20-F
Annual reportOct 30, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
242526
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CUVL · research, not advice